Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients

Eva Obermayr, Fatima Sanchez-Cabo, Muy-Kheng M Tea, Christian F Singer, Michael Krainer, Michael B Fischer, Jalid Sehouli, Alexander Reinthaller, Reinhard Horvat, Georg Heinze, Dan Tong, Robert Zeillinger, Eva Obermayr, Fatima Sanchez-Cabo, Muy-Kheng M Tea, Christian F Singer, Michael Krainer, Michael B Fischer, Jalid Sehouli, Alexander Reinthaller, Reinhard Horvat, Georg Heinze, Dan Tong, Robert Zeillinger

Abstract

Background: The presence of circulating tumor cells (CTC) in the peripheral blood of cancer patients has been described for various solid tumors and their clinical relevance has been shown. CTC detection based on the analysis of epithelial antigens might be hampered by the genetic heterogeneity of the primary tumor and loss of epithelial antigens. Therefore, we aimed to identify new gene markers for the PCR-based detection of CTC in female cancer patients.

Methods: Gene expression of 38 cancer cell lines (breast, ovarian, cervical and endometrial) and of 10 peripheral blood mononuclear cell (PBMC) samples from healthy female donors was measured using microarray technology (Applied Biosystems). Differentially expressed genes were identified using the maxT test and the 50% one-sided trimmed maxT-test. Confirmatory RT-qPCR was performed for 380 gene targets using the AB TaqMan® Low Density Arrays. Then, 93 gene targets were analyzed using the same RT-qPCR platform in tumor tissues of 126 patients with primary breast, ovarian or endometrial cancer. Finally, blood samples from 26 healthy women and from 125 patients (primary breast, ovarian, cervical, or endometrial cancer, and advanced breast cancer) were analyzed following OncoQuick enrichment and RNA pre-amplification. Likewise, hMAM and EpCAM gene expression was analyzed in the blood of breast and ovarian cancer patients. For each gene, a cut-off threshold value was set at three standard deviations from the mean expression level of the healthy controls to identify potential markers for CTC detection.

Results: Six genes were over-expressed in blood samples from 81% of patients with advanced and 29% of patients with primary breast cancer. EpCAM gene expression was detected in 19% and 5% of patients, respectively, whereas hMAM gene expression was observed in the advanced group (39%) only. Multimarker analysis using the new six gene panel positively identified 44% of the cervical, 64% of the endometrial and 19% of the ovarian cancer patients.

Conclusions: The panel of six genes was found superior to EpCAM and hMAM for the detection of circulating tumor cells in the blood of breast cancer, and they may serve as potential markers for CTC derived from endometrial, cervical, and ovarian cancers.

Figures

Figure 1
Figure 1
Graphical scheme of the experimental plan. Following a step down strategy, six genes from initially 27.686 genes were identified as new gene markers for the RT-qPCR based detection of circulating tumor cells (CTC). In microarray analysis, we compared expression profiles of PBMC isolated by Ficoll gradient centrifugation from healthy individuals and various established cancer cell lines. In microarray validation, we compared expression profiles of PBMC isolated by Oncoquick from healthy individuals and cell lines. cDNA was amplified according to a published protocol [25]. For the experimental analysis of patients samples, we used Oncoquick only. cDNA was amplified using the TargetAmp™1-Round aRNA Amplification Kit.
Figure 2
Figure 2
Sensitivity of RT-qPCR using TLDA platform. Expression levels of 93 candidate genes were analyzed using cDNA generated from total RNA isolated from peripheral blood samples from a healthy female donor and the same blood spiked with 4, 40 and 400 T47-D tumor cells after cell enrichment. RNA was pre-amplified using the TargetAmp™1-Round aRNA Amplification Kit. Average Ct values obtained from RT-qPCR amplification of CCNE2, DKFZp762E1312, EMP2, MAL2, PPIC, and SLC6A8 transcripts using the TLDA format are shown. MAL2 and CCNE2 gene expression was below the detection limit of RT-qPCR in the unspiked blood. The detection sensitivity of the respective marker gene was estimated to be 40 and 400 tumor cells per 15 ml whole blood.
Figure 3
Figure 3
RT-qPCR analysis of marker gene expression in peripheral blood. Gene expression was analyzed in blood samples taken from patients (triangles) with recurrent breast cancer (A), and in blood samples taken at first diagnosis from breast (B), endometrial (C), cervical (D) and ovarian (E) cancer patients. Blood from healthy females (circles) served as a control group. Mononuclear cells were enriched with the Oncoquick density gradient. RT-qPCR was performed following a RNA pre-amplification step. Average Ct values obtained from duplicates were normalized to GAPDH gene expression. Cut-off threshold values calculated from the mean average normalized gene expression in healthy female blood as indicated by horizontal lines for the respective gene markers (DKFZp762E1312 1.39, SLC6A8 2.92, PPIC 3.61, EMP2 6.84, MAL2 14.61, CCNE2 16.83).

References

    1. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide.
    1. Ashworth T. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aus Med J. 1869;14:146–149.
    1. Paterlini-Brechot P, Benali NL. Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett. 2007;253(2):180–204. doi: 10.1016/j.canlet.2006.12.014.
    1. Smerage JB, Hayes DF. The measurement and therapeutic implications of circulating tumour cells in breast cancer. Br J Cancer. 2006;94(1):8–12. doi: 10.1038/sj.bjc.6602871.
    1. Lacroix M. Significance, detection and markers of disseminated breast cancer cells. Endocr Relat Cancer. 2006;13(4):1033–1067. doi: 10.1677/ERC-06-0001.
    1. Zieglschmid V, Hollmann C, Bocher O. Detection of disseminated tumor cells in peripheral blood. Crit Rev Clin Lab Sci. 2005;42(2):155–196. doi: 10.1080/10408360590913696.
    1. Marth C, Kisic J, Kaern J, Trope C, Fodstad O. Circulating tumor cells in the peripheral blood and bone marrow of patients with ovarian carcinoma do not predict prognosis. Cancer. 2002;94(3):707–712. doi: 10.1002/cncr.10250.
    1. Wimberger P, Heubner M, Otterbach F, Fehm T, Kimmig R, Kasimir-Bauer S. Influence of platinum-based chemotherapy on disseminated tumor cells in blood and bone marrow of patients with ovarian cancer. Gynecol Oncol. 2007;107(2):331–338. doi: 10.1016/j.ygyno.2007.07.073.
    1. Diddle AW, Sholes DM, Hollingsworth J, Kinlaw S. Cervical carcinoma; cancer cells in the circulating blood. Am J Obstet Gynecol. 1959;78:582–585.
    1. Yabushita H, Shimazu M, Yamada H, Sawaguchi K, Noguchi M, Nakanishi M, Kawai M. Occult lymph node metastases detected by cytokeratin immunohistochemistry predict recurrence in node-negative endometrial cancer. Gynecol Oncol. 2001;80(2):139–144. doi: 10.1006/gyno.2000.6067.
    1. Ji XQ, Sato H, Tanaka H, Konishi Y, Fujimoto T, Takahashi O, Tanaka T. Real-time quantitative RT-PCR detection of disseminated endometrial tumor cells in peripheral blood and lymph nodes using the LightCycler System. Gynecol Oncol. 2006;100(2):355–360. doi: 10.1016/j.ygyno.2005.08.041.
    1. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW. et al.Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351(8):781–791. doi: 10.1056/NEJMoa040766.
    1. Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, Doyle GV, Matera J, Allard WJ, Miller MC. et al.Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol. 2005;23(7):1420–1430. doi: 10.1200/JCO.2005.08.140.
    1. Pachmann K, Camara O, Kavallaris A, Schneider U, Schunemann S, Hoffken K. Quantification of the response of circulating epithelial cells to neodadjuvant treatment for breast cancer: a new tool for therapy monitoring. Breast Cancer Res. 2005;7(6):R975–979. doi: 10.1186/bcr1328.
    1. Cristofanilli M, Broglio KR, Guarneri V, Jackson S, Fritsche HA, Islam R, Dawood S, Reuben JM, Kau SW, Lara JM. et al.Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden. Clin Breast Cancer. 2007;7(6):471–479. doi: 10.3816/CBC.2007.n.004.
    1. Sieuwerts AM, Kraan J, Bolt J, van der Spoel P, Elstrodt F, Schutte M, Martens JW, Gratama JW, Sleijfer S, Foekens JA. Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst. 2009;101(1):61–66.
    1. Medical devices; immunology and microbiology devices; classification of the immunomagnetic circulating cancer cell selection and enumeration system. Final rule. Fed Regist. 2004;69(91):26036–26038.
    1. Zhong XY, Kaul S, Eichler A, Bastert G. Evaluating GA733-2 mRNA as a marker for the detection of micrometastatic breast cancer in peripheral blood and bone marrow. Arch Gynecol Obstet. 1999;263(1-2):2–6. doi: 10.1007/s004040050251.
    1. Stathopoulou A, Mavroudis D, Perraki M, Apostolaki S, Vlachonikolis I, Lianidou E, Georgoulias V. Molecular detection of cancer cells in the peripheral blood of patients with breast cancer: comparison of CK-19, CEA and maspin as detection markers. Anticancer Res. 2003;23(2C):1883–1890.
    1. Stathopoulou A, Angelopoulou K, Perraki M, Georgoulias V, Malamos N, Lianidou E. Quantitative RT-PCR luminometric hybridization assay with an RNA internal standard for cytokeratin-19 mRNA in peripheral blood of patients with breast cancer. Clin Biochem. 2001;34(8):651–659. doi: 10.1016/S0009-9120(01)00276-4.
    1. Roncella S, Ferro P, Bacigalupo B, Pronzato P, Tognoni A, Falco E, Gianquinto D, Ansaldo V, Dessanti P, Fais F. et al.Human mammaglobin mRNA is a reliable molecular marker for detecting occult breast cancer cells in peripheral blood. J Exp Clin Cancer Res. 2005;24(2):265–271.
    1. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J. et al.Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5(10):R80. doi: 10.1186/gb-2004-5-10-r80.
    1. Ge YDS, Speed TP. Resampling-based multiple testing for microarray data analysis. Test. 2003;12:1–44. doi: 10.1007/BF02595811.
    1. Gleiss A, Sanchez-Cabo F, Perco P, Tong D, Heinze G. Adaptive trimmed t-statistics for identifying predominantly high expression in a microarray experiment. Stat Med. in press .
    1. Klein CA, Seidl S, Petat-Dutter K, Offner S, Geigl JB, Schmidt-Kittler O, Wendler N, Passlick B, Huber RM, Schlimok G. et al.Combined transcriptome and genome analysis of single micrometastatic cells. Nat Biotechnol. 2002;20(4):387–392. doi: 10.1038/nbt0402-387.
    1. Mikhitarian K, Martin RH, Ruppel MB, Gillanders WE, Hoda R, Schutte del H, Callahan K, Mitas M, Cole DJ. Detection of mammaglobin mRNA in peripheral blood is associated with high grade breast cancer: interim results of a prospective cohort study. BMC Cancer. 2008;8:55. doi: 10.1186/1471-2407-8-55.
    1. Zeillinger R, Fabjani G. Method and kit for diagnosis of a cancerous disease, method for determining the reaction of a patient to the treatment for a cancerous disease, medicament for the prophylaxis or treatment of a cancerous disease. European Patent No. 1786929. 2006.
    1. Gervasoni A, Monasterio Munoz RM, Wengler GS, Rizzi A, Zaniboni A, Parolini O. Molecular signature detection of circulating tumor cells using a panel of selected genes. Cancer Lett. 2008;263(2):267–279. doi: 10.1016/j.canlet.2008.01.003.
    1. Konigsberg R, Gneist M, Jahn-Kuch D, Pfeiler G, Hager G, Hudec M, Dittrich C, Zeillinger R. Circulating tumor cells in metastatic colorectal cancer: efficacy and feasibility of different enrichment methods. Cancer Lett. pp. 117–123.
    1. Lauper N, Beck AR, Cariou S, Richman L, Hofmann K, Reith W, Slingerland JM, Amati B. Cyclin E2: a novel CDK2 partner in the late G1 and S phases of the mammalian cell cycle. Oncogene. 1998;17(20):2637–2643. doi: 10.1038/sj.onc.1202477.
    1. Muller V, Stahmann N, Riethdorf S, Rau T, Zabel T, Goetz A, Janicke F, Pantel K. Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res. 2005;11(10):3678–3685. doi: 10.1158/1078-0432.CCR-04-2469.
    1. Forozan F, Karhu R, Kononen J, Kallioniemi A, Kallioniemi OP. Genome screening by comparative genomic hybridization. Trends Genet. 1997;13(10):405–409. doi: 10.1016/S0168-9525(97)01244-4.
    1. Knuutila S, Bjorkqvist AM, Autio K, Tarkkanen M, Wolf M, Monni O, Szymanska J, Larramendy ML, Tapper J, Pere H. et al.DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies. Am J Pathol. 1998;152(5):1107–1123.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever